Skip to main content
OpenTrials
Completed

NCT Number: NCT04757272

Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?

Modulation of the renin angiotensin system by the chronic hepatitis C virus treatment either by (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Corona Virus Infection Coronaviridae Infections Coronavirus Infections Digestive System Diseases Hepatitis Infections Liver Diseases Nidovirales Infections RNA Virus Infections Virus Diseases

Age range

21 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Zagazig University Hospitals

Zagazig, Sharqia Province, 44519, Egypt

About this study

The interaction of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and the renin angiotensin system (RAS) via angiotensin converting enzyme-2 (ACE-2), the receptor used by the SARS-CoV-2 to gain access to cells could provide an explanation for the several unusual clinical findings observed in COVID-19 Although chronic hepatitis is one of the risk factors listed by WHO for severe COVID-19, low incidence of COVID-19 was observed among HCV patients admitted to Egyptian hospitals.

Modulation of the RAS by the chronic hepatitis C virus treatment either by (ACEI or ARBS), (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All consecutive patients who were diagnosed to have COVID-19 and admitted to Zagazig University Hospitals during the period from May 2020 to January 2021

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. incidence of chronic hepatitis C among COVID-19 hospitalized patients.

    Time frame: 7 months

    incidence of chronic hepatitis C among COVID-19 hospitalized patients.

Secondary outcomes

  1. the impact of previous exposure to different HCV management protocols on the clinical characteristics and outcome of COVID-19 among COVID-19 hospitalized patients

    Time frame: 7 months

    the impact of previous exposure to different HCV management protocols on the clinical characteristics and outcome of COVID-19 among COVID-19 hospitalized patients

Sponsors and collaborators

Lead sponsor

Zagazig University

Other Gov

Registry information

Official study title

Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019 (COVID-19)?

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Feb 17, 2021
Registry last updated
Sep 30, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.